Köksal, MerveKoçak, GökçeÖztürk, YusufTufan, Ali Evren2023-11-222023-11-222022Köksal, M., Koçak, G., Öztürk, Y., & Tufan, A. E. (2022). A Case of Emetophobia Responding to Mirtazapine and Propranolol Treatment. Journal of Neurogastroenterology and Motility, 28(4), 709-710.2093-08792093-0887http://dx.doi.org/10.5056/jnm22133https://hdl.handle.net/20.500.12491/11870Emetophobia (“phobia of vomiting and nausea” or “Specific Phobia- Other [Vomiting]” in Diagnostic and statistical manual of mental disorders-Fifth Edition [DSM-5]) is characterized by impairing, chronic phobic avoidance of nausea/vomiting as well as inordinate cognitive and autonomic responses when avoidance is not possible.1,2 Patients may have elevated disgust sensitivity, a tendency to display gastrointestinal symptoms of anxiety as well as misinterpretation of those symptoms as catastrophic.2 Data on pharmacological management of emetophobia among adolescents is limited with only 2 cases benefiting from selective serotonin reuptake inhibitors (fluoxetine and sertraline) while adults may also benefit from benzodiazepines. 3-5 Patients may apply to various medical specialty clinics for treatment and this may delay diagnosis and management. Here; we aim to present an adolescent with emetophobia and its management by mirtazapine and propranolol.eninfo:eu-repo/semantics/openAccessEmetophobiaSerotoninPropranolol TreatmentLetter10.5056/jnm22133284709710362503772-s2.0-85141550518Q2WOS:000877926500018Q2